Then, we respectively compared the difference in the proportions of immune cell subsets in the CB and NB groups, and found that: at baseline, compared with NB group, the CB group had a significantly higher proportion of effective CD4+T cell (E4, CD4+CD45RA+CD197−), with marginal statistical significance (P = 0.055) (Fig. 3B), while after 2 cycles of treatment, there was no significant difference in the proportions of immune cell subsets (Fig. 3C). The gene discussed is CCR7; the disease is neuroblastoma.